Lowest-Rated StocksLowest-RatedNASDAQ:FATE Fate Therapeutics (FATE) Stock Forecast, Price & News $2.18 +0.08 (+3.81%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$2.03▼$2.1950-Day Range$2.02▼$4.4652-Week Range$1.99▼$23.96Volume1.54 million shsAverage Volume3.27 million shsMarket Capitalization$214.86 millionP/E RatioN/ADividend YieldN/APrice Target$12.96 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Fate Therapeutics MarketRank™ ForecastAnalyst RatingHold2.15 Rating ScoreUpside/Downside494.6% Upside$12.96 Price TargetShort InterestBearish26.17% of Float Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment1.37Based on 2 Articles This WeekInsider TradingSelling Shares$59,353 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.91) to ($2.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector195th out of 969 stocksBiological Products, Except Diagnostic Industry26th out of 161 stocks 4.1 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.15, and is based on 5 buy ratings, 13 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.96, Fate Therapeutics has a forecasted upside of 494.6% from its current price of $2.18.Amount of Analyst CoverageFate Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted26.17% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Fate Therapeutics has recently decreased by 12.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next 3.5 News and Social Media Coverage News SentimentFate Therapeutics has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Fate Therapeutics this week, compared to 4 articles on an average week.Search Interest4 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,353.00 in company stock.Percentage Held by InsidersOnly 5.04% of the stock of Fate Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.91) to ($2.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fate Therapeutics (NASDAQ:FATE) StockFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More FATE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FATE Stock News HeadlinesSeptember 7, 2023 | msn.comCantor Fitzgerald Reiterates Fate Therapeutics (FATE) Neutral RecommendationAugust 31, 2023 | finance.yahoo.comFate Therapeutics to Present at Upcoming September Investor ConferencesSeptember 29, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 17, 2023 | msn.comTruist Securities Reiterates Fate Therapeutics (FATE) Hold RecommendationAugust 16, 2023 | msn.comFate Therapeutics: Not Now, Maybe Never?August 16, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Fate TherapeuticsAugust 11, 2023 | msn.comMorgan Stanley Maintains Fate Therapeutics (FATE) Equal-Weight RecommendationAugust 10, 2023 | msn.comEF Hutton Reiterates Fate Therapeutics (FATE) Buy RecommendationSeptember 29, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 10, 2023 | msn.comBMO Capital Maintains Fate Therapeutics (FATE) Market Perform RecommendationAugust 9, 2023 | finance.yahoo.comFATE Q2 Earnings Beat on Lower Expenses, Revenues MissAugust 8, 2023 | finance.yahoo.comFate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue EstimatesAugust 8, 2023 | finance.yahoo.comFate Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesJuly 28, 2023 | finance.yahoo.comFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial ResultsJuly 22, 2023 | finance.yahoo.comOne Fate Therapeutics Insider Raised Stake By 83% In Previous YearJuly 17, 2023 | finance.yahoo.comCytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical OfficerJuly 1, 2023 | finance.yahoo.comWe Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth CarefullyJuly 1, 2023 | businesswire.comFATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATEJune 7, 2023 | finance.yahoo.comWhy Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?June 5, 2023 | finance.yahoo.comMonoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the DomainJune 4, 2023 | finance.yahoo.comFate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For ExcitementJune 2, 2023 | finance.yahoo.comFate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound?May 31, 2023 | finance.yahoo.comFate Therapeutics to Present at Upcoming June Investor ConferencesMay 23, 2023 | msn.comFate Therapeutics: The Future Remains CloudyMay 16, 2023 | marketwatch.comNatural Killer Cells Therapeutics Market Analysis 2023-2030May 8, 2023 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Fate Therapeutics, Inc. (FATE)May 8, 2023 | finance.yahoo.comBroker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging HigherSee More Headlines Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Company Calendar Last Earnings8/08/2023Today9/29/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees551Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.96 High Stock Price Forecast$65.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+494.6%Consensus RatingHold Rating Score (0-4)2.15 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-281,720,000.00 Net Margins-177.41% Pretax Margin-177.41% Return on Equity-44.14% Return on Assets-31.69% Debt Debt-to-Equity RatioN/A Current Ratio8.78 Quick Ratio8.78 Sales & Book Value Annual Sales$96.30 million Price / Sales2.23 Cash FlowN/A Price / Cash FlowN/A Book Value$4.98 per share Price / Book0.44Miscellaneous Outstanding Shares98,560,000Free Float93,594,000Market Cap$214.86 million OptionableOptionable Beta1.47 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. J. Scott Wolchko (Age 53)Founder, CEO, Pres & Director Comp: $645kMr. Edward J. Dulac III (Age 47)Chief Financial Officer Comp: $455kMs. Cindy R. Tahl (Age 50)Gen. Counsel & Corp. Sec. Comp: $455kDr. Bahram Valamehr Ph.D. (Age 46)Chief R&D Officer Comp: $455kMr. Jim Beitel M.B.A.Sr. VP of Corp. Devel.Dr. Jerome Bressi Ph.D.Sr. VP of Regulatory & QualityMore ExecutivesKey CompetitorsSutro BiopharmaNASDAQ:STROMesoblastNASDAQ:MESOInnate PharmaNASDAQ:IPHATenaya TherapeuticsNASDAQ:TNYATaysha Gene TherapiesNASDAQ:TSHAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 21,723 shares on 9/21/2023Ownership: 0.486%Virginia Retirement Systems ET ALBought 33,600 shares on 8/22/2023Ownership: 0.034%Edward J Dulac IIISold 4,718 sharesTotal: $13,210.40 ($2.80/share)Coppell Advisory Solutions LLCBought 8,865 shares on 8/17/2023Ownership: 0.009%Capital Impact Advisors LLCBought 4,421 shares on 8/15/2023Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions FATE Stock - Frequently Asked Questions Should I buy or sell Fate Therapeutics stock right now? 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks. What is Fate Therapeutics' stock price forecast for 2023? 20 brokerages have issued 1 year price objectives for Fate Therapeutics' stock. Their FATE share price forecasts range from $5.00 to $65.00. On average, they predict the company's share price to reach $12.96 in the next year. This suggests a possible upside of 494.6% from the stock's current price. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. How have FATE shares performed in 2023? Fate Therapeutics' stock was trading at $10.09 at the start of the year. Since then, FATE stock has decreased by 78.4% and is now trading at $2.18. View the best growth stocks for 2023 here. Are investors shorting Fate Therapeutics? Fate Therapeutics saw a decrease in short interest in September. As of September 15th, there was short interest totaling 24,290,000 shares, a decrease of 12.1% from the August 31st total of 27,640,000 shares. Based on an average daily volume of 2,280,000 shares, the days-to-cover ratio is presently 10.7 days. Currently, 26.2% of the shares of the stock are sold short. View Fate Therapeutics' Short Interest. When is Fate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our FATE earnings forecast. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. The biopharmaceutical company earned $0.93 million during the quarter, compared to the consensus estimate of $5.41 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 44.14% and a negative net margin of 177.41%. Fate Therapeutics's quarterly revenue was down 95.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.79) EPS. What ETF holds Fate Therapeutics' stock ? iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio. What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). What is Fate Therapeutics' stock symbol? Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE." How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fate Therapeutics' stock price today? One share of FATE stock can currently be purchased for approximately $2.18. How much money does Fate Therapeutics make? Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $214.86 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis. How many employees does Fate Therapeutics have? The company employs 551 workers across the globe. How can I contact Fate Therapeutics? Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com. This page (NASDAQ:FATE) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.